Previous 10 | Next 10 |
Study Demonstrated Superiority of Cingal, a Single-Injection Hyaluronic Acid-Based Viscosupplement Combined with Fast-Acting Steroid, Over Steroid Alone, for Osteoarthritis Pain Relief at 26 Weeks Study Builds on Prior Phase III Study Data that Demonstrated Superiority over Plac...
BEDFORD, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its third quarter 2022 financial results after the close of the market on Tue...
BEDFORD, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced the limited market release and the first surgeries performed using the X-Twist Fixation System. Chr...
Anika Therapeutics, Inc. (ANIK) Q2 2022 Earnings Conference Call August 03, 2022, 05:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations, ESG and Corporate Communications Cheryl Blanchard - President and Chief Executive Officer Michae...
The following slide deck was published by Anika Therapeutics, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Anika Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation
Anika Therapeutics press release ( NASDAQ: ANIK ): Q2 Non-GAAP EPS of -$0.12 beats by $0.09 . Revenue of $39.7M (+4.2% Y/Y) beats by $1.85M . The Company continues to expect its overall revenue for fiscal year 2022 to be toward the upper end of its guidance ran...
Second quarter revenue growth up 4% X-Twist ™ 510(k) clearance received; Limited market release on schedule for 2H 2022 BEDFORD, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in earl...
Anika Therapeutics ( NASDAQ: ANIK ) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, after market close. The consensus EPS Estimate is -$0.21 (-333.3% Y/Y) and the consensus Revenue Estimate is $37.85M (-0.7% Y/Y). Over the last 2 years, ANIK ha...
BEDFORD, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has received the Accelerating the Cutting Edge (ACE) Award from the American Orthopaedic...
BEDFORD, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2022 financial results after the close of the market on We...
News, Short Squeeze, Breakout and More Instantly...
Anika Therapeutics Inc. Company Name:
ANIK Stock Symbol:
NASDAQ Market:
Anika Therapeutics Inc. Website:
Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika’s proprietary hyaluronic acid (HA) regenerative portfolio Over 300 surgeries completed during the limited market release, highlighting the growing interest and commerci...
2024-07-09 17:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-29 13:30:02 ET Stephens analyst issues EQUAL-WEIGHT recommendation for ANIK on May 29, 2024 12:00PM ET. The previous analyst recommendation was Equal-Weight. ANIK was trading at $25.32 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...